A New Era in Endometrial Cancer Treatment: FDA Approves Jemperli

In July 2024, the FDA approved Jemperli (dostarlimab-gxly), a groundbreaking therapy for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). This approval provides a new frontline treatment option for a cancer type that previously had limited options.

Jemperli, a PD-1 blocking antibody, enhances the immune system's ability to target and destroy cancer cells. Its efficacy was demonstrated in the RUBY Part 1 trial, which showed significant improvements in progression-free survival (PFS) and overall survival (OS) when combined with carboplatin and paclitaxel, followed by Jemperli alone.

For more information on Jemperli and its impact on endometrial cancer treatment, visit the FDA announcement.